Identifying cancer subtypes based on embryonic and hematopoietic stem cell signatures in pan-cancer.

IF 4.9 2区医学 Q2 CELL BIOLOGY

Cellular Oncology Pub Date : 2024-04-01 Epub Date: 2023-10-12 DOI:10.1007/s13402-023-00886-7

Jiali Lei, Jiangti Luo, Qian Liu, Xiaosheng Wang

{"title":"Identifying cancer subtypes based on embryonic and hematopoietic stem cell signatures in pan-cancer.","authors":"Jiali Lei, Jiangti Luo, Qian Liu, Xiaosheng Wang","doi":"10.1007/s13402-023-00886-7","DOIUrl":null,"url":null,"abstract":"Purpose: Cancer cells with stem cell-like properties may contribute to cancer development and therapy resistance. The advancement of multi-omics technology has sparked interest in exploring cancer stemness from a multi-omics perspective. However, there is a limited number of studies that have attempted to subtype cancer by combining different types of stem cell signatures.Methods: In this study, 10,323 cancer specimens from 33 TCGA cancer types were clustered based on the enrichment scores of six stemness gene sets, representing two types of stem cell backgrounds: embryonic stem cells (ESCs) and hematopoietic stem cells (HSCs).Results: We identified four subtypes of pan-cancer, termed StC1, StC2, StC3 and StC4, which displayed distinct molecular and clinical features, including stemness, genome integrity, intratumor heterogeneity, methylation levels, tumor microenvironment, tumor progression, responses to chemotherapy and immunotherapy, and survival prognosis. Importantly, this subtyping method for pan-cancer is reproducible at the protein level.Conclusion: Our findings indicate that the ESC signature is an adverse prognostic factor in cancer, while the HSC signature and ratio of HSC/ESC signatures are positive prognostic factors. The subtyping of cancer based on ESC and HSC signatures may provide insights into cancer biology and clinical implications of cancer.","PeriodicalId":49223,"journal":{"name":"Cellular Oncology","volume":" ","pages":"587-605"},"PeriodicalIF":4.9000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13402-023-00886-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Cancer cells with stem cell-like properties may contribute to cancer development and therapy resistance. The advancement of multi-omics technology has sparked interest in exploring cancer stemness from a multi-omics perspective. However, there is a limited number of studies that have attempted to subtype cancer by combining different types of stem cell signatures.

Methods: In this study, 10,323 cancer specimens from 33 TCGA cancer types were clustered based on the enrichment scores of six stemness gene sets, representing two types of stem cell backgrounds: embryonic stem cells (ESCs) and hematopoietic stem cells (HSCs).

Results: We identified four subtypes of pan-cancer, termed StC1, StC2, StC3 and StC4, which displayed distinct molecular and clinical features, including stemness, genome integrity, intratumor heterogeneity, methylation levels, tumor microenvironment, tumor progression, responses to chemotherapy and immunotherapy, and survival prognosis. Importantly, this subtyping method for pan-cancer is reproducible at the protein level.

Conclusion: Our findings indicate that the ESC signature is an adverse prognostic factor in cancer, while the HSC signature and ratio of HSC/ESC signatures are positive prognostic factors. The subtyping of cancer based on ESC and HSC signatures may provide insights into cancer biology and clinical implications of cancer.

Abstract Image

查看原文本刊更多论文

基于胚胎干细胞和造血干细胞特征识别癌症亚型。

目的：具有干细胞样特性的癌症细胞可能有助于癌症的发展和治疗耐药性。多组学技术的进步激发了人们从多组学角度探索癌症干性的兴趣。然而，有有限数量的研究试图通过结合不同类型的干细胞特征来亚型癌症。方法：根据胚胎干细胞（ESCs）和造血干细胞（HSCs）两种干细胞背景的6个干细胞基因集的富集分数，对33种TCGA癌症类型的10323份癌症标本进行聚类。结果：我们确定了四种全癌亚型，称为StC1、StC2、StC3和StC4，它们表现出不同的分子和临床特征，包括干性、基因组完整性、肿瘤内异质性、甲基化水平、肿瘤微环境、肿瘤进展、对化疗和免疫疗法的反应以及生存预后。重要的是，这种泛癌基因的亚型方法在蛋白质水平上是可重复的。结论：ESC信号是癌症的一个不利预后因素，而HSC信号和HSC/ESC信号的比例是积极的预后因素。基于ESC和HSC特征的癌症亚型可能提供对癌症生物学和癌症临床意义的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cellular Oncology ONCOLOGY-CELL BIOLOGY

CiteScore

10.30

自引率

1.50%

发文量

审稿时长

12 months

期刊介绍： The Official Journal of the International Society for Cellular Oncology Focuses on translational research Addresses the conversion of cell biology to clinical applications Cellular Oncology publishes scientific contributions from various biomedical and clinical disciplines involved in basic and translational cancer research on the cell and tissue level, technical and bioinformatics developments in this area, and clinical applications. This includes a variety of fields like genome technology, micro-arrays and other high-throughput techniques, genomic instability, SNP, DNA methylation, signaling pathways, DNA organization, (sub)microscopic imaging, proteomics, bioinformatics, functional effects of genomics, drug design and development, molecular diagnostics and targeted cancer therapies, genotype-phenotype interactions. A major goal is to translate the latest developments in these fields from the research laboratory into routine patient management. To this end Cellular Oncology forms a platform of scientific information exchange between molecular biologists and geneticists, technical developers, pathologists, (medical) oncologists and other clinicians involved in the management of cancer patients. In vitro studies are preferentially supported by validations in tumor tissue with clinicopathological associations.